The Comparison of Inflammatory Cytokines (IL-6 and IL-18) and Immune Cells in Japanese Encephalitis Patients With Different Progression

Yun Zhou, Peiyu Bian, Hong Du, Tao Wang, Mengyuan Li, Haifeng Hu, Chuantao Ye, Xuyang Zheng, Ying Zhang, Yinfeng Lei, Zhansheng Jia, Jianqi LianFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

Japanese Encephalitis (JE) remains a significant threat, particularly in Asia, with high mortality and long-term neurological sequelae. This study identifies elevated levels of inflammatory cytokines IL-6 and IL-18, alongside a reduced presence of CD4+ T and B immune cells, as potential biomarkers for poor prognosis in JE patients.

What Problem Does This Paper Address?

Japanese Encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a serious neurological disease prevalent in Asia. Despite advancements in supportive care, the fatality rate remains around 30%, and a significant portion of survivors experience debilitating neuropsychiatric issues. Currently, there's no specific antiviral therapy for JE, and understanding the factors that predict a patient's outcome is crucial for better clinical management. This paper aims to identify specific inflammatory markers and immune cell profiles that correlate with the severity and prognosis of JE in adult patients.

Methods

The researchers conducted a retrospective cohort study involving 149 patients diagnosed with JE. They collected blood samples from patients upon admission and, for severe cases, at intervals during their hospital stay.

  • Cytokine Analysis: A Luminex assay was used to measure the levels of various cytokines in patient plasma. This allowed for the comparison of cytokine profiles between healthy individuals, mild JE patients, and severe JE patients, as well as dynamic monitoring in severe cases.
  • Immune Cell Profiling: Flow cytometry was employed to analyze the proportions of different immune cell populations, specifically T cells (CD3+, CD4+, CD8+), B cells (CD19+), monocytes (CD14+), and NK cells (CD56+), in peripheral blood mononuclear cells (PBMCs). This was done to assess how these cell counts differed between healthy individuals, surviving JE patients, and fatal JE cases.
  • Statistical Analysis: Standard statistical methods, including one-way ANOVA and Mann-Whitney U tests, were used to compare groups and analyze the data.

Datasets

The study utilized data from 149 JE patients admitted to Tangdu Hospital between January 2014 and October 2018. A control group of 6 healthy volunteers was also included for comparison. The data collected included patient demographics, clinical manifestations, hospitalization duration, and laboratory measurements of cytokines and immune cells. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Inflammatory Cytokines as Prognostic Indicators: The consistent elevation of IL-6 and IL-18 in the plasma of JE patients, particularly those with fatal outcomes, suggests these cytokines are not just markers of inflammation but may actively contribute to disease severity and predict a poorer prognosis.
  • Immune Cell Imbalance in Severe JE: A significant finding is the reduced proportion of CD4+ T cells and B cells in the PBMCs of severe JE patients, especially those who did not survive. This points towards a critical role for these adaptive immune cells in controlling the virus and suggests their depletion is a hallmark of severe disease progression.
  • Adults as a Vulnerable Population: The study highlights an increasing incidence of JE in adult and older populations, contrasting with the previously observed higher prevalence in children. This shift may be influenced by changing socio-environmental factors and underscores the need for continued vigilance and research across all age groups.
  • Dynamic Changes Matter: Monitoring cytokine and immune cell levels dynamically over the course of the disease, particularly in severe cases, provides a more nuanced understanding of disease progression and potential therapeutic targets.

Key Results

  • Elevated IL-6 and IL-18: JE patients, especially those with fatal outcomes, showed significantly higher levels of IL-6 and IL-18 in their plasma compared to healthy controls.
  • Decreased CD4+ T and B Cells: Severe JE patients, particularly those with fatal outcomes, exhibited a decreased percentage of CD4+ T cells and B cells in their PBMCs compared to surviving patients and healthy controls.
  • Age Distribution: The study observed a higher proportion of adult and older patients (over 20 years old) among the JE cases, accounting for nearly 90% of the total.
  • Hospitalization Duration: Severe JE patients required significantly longer hospitalization periods compared to mild cases.

Limitations and Future Work

The authors acknowledge several limitations:

  • Timing of Samples: For some analyses, data represented an average over different disease stages, rather than precise acute-phase measurements. This could influence the interpretation of cytokine dynamics.
  • Sample Size for Dynamic Analysis: The dynamic analysis of cytokines in severe patients involved a small number of fatal (four) and surviving (seven) cases, limiting the statistical power for definitive conclusions.
  • Vaccination Status: The study population included individuals of various ages, and it was noted that most patients over 30 years old were likely unvaccinated. The impact of vaccination status on immune responses and disease progression was not explicitly controlled for and warrants further investigation.
  • Viral Genotype: The study did not analyze the JEV genotype, which could potentially influence disease outcome.

Future work should focus on larger cohort studies to validate these findings, particularly the role of IL-6, IL-18, CD4+ T cells, and B cells as prognostic markers. Further research into the interplay between innate and adaptive immune cells and their correlation with JE prognosis is also recommended. Investigating the impact of JEV genotypes and vaccination status on disease progression would also be valuable.

Summary updated

Abstract

The consistent high level of IL-6 and IL-18 in the plasma and low proportion of CD4<sup>+</sup> T and B cells in the PBMCs might be the indicators of poor prognosis.
BibTeX
@inproceedings{zhou2022comparison,
  author = {Yun Zhou and Peiyu Bian and Hong Du and Tao Wang and Mengyuan Li and Haifeng Hu and Chuantao Ye and Xuyang Zheng and Ying Zhang and Yinfeng Lei and Zhansheng Jia and Jianqi Lian},
  title = {{The Comparison of Inflammatory Cytokines (IL-6 and IL-18) and Immune Cells in Japanese Encephalitis Patients With Different Progression}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.826603},
}
Figure